Health Catalyst Capital Management
Investments
22Portfolio Exits
2Funds
2About Health Catalyst Capital Management
Health Catalyst Capital Management is an independent private equity fund investing in growth-stage healthcare technology and technology-enabled services businesses that seek to improve the human condition and promote value-based care. Current and former investments include Cardiogram, PierianDx, Medal, Risalto, HealthMine, ReferWell, InsightIn, Artimis, 1DocWay, Board Vitals, Clareto and others.
Health Catalyst Capital Management Headquarter Location
515 Madison Avenue
New York, New York, 10022,
United States
212-752-2225
Health Catalyst Capital Management Web Traffic
Health Catalyst Capital Management Rank
Latest Health Catalyst Capital Management News
Nov 14, 2019
After fueling its seed round last year, Health Catalyst Capital Management again lead the startup's funding. Share Musculoskeletal digital health platform Risalto Health bagged $7 million in new funding from Health Catalyst Capital Management, the startup announced yesterday. WHAT THEY DO The New York-based company use artificial intelligence to find muscular and skeletal health providers in the user’s area. Patients navigate these selections through the company’s app, which acts as a digital concierge that helps select prompt, appropriate care for their condition. Risalto aims to partner with payers and providers alike to streamline patients’ access to care. According to the company, the platform has been shown to reduce patients’ pain scores by as much as 50%, and influences members’ care choices at a 95% success rate. Alongside Health Catalyst Capital Management, the company boasts Oxeon Venture Studio as an institutional investor. WHAT IT’S FOR In addition to funding improvements to the platform itself, Risalto said that these new dollars will help scale the digital musculoskeletal program across the nation. "Each day we spend working with patients it becomes more apparent that there is a lack of coordination and vital resources for those with MSK issues," Dr. Daniel Pizzarello, founder and CEO of Risalto, said in a statement. "We're excited to continue our partnership with HCCM to scale nationwide and help ensure that every patient gets the care that they deserve so that they can avoid dangerous drugs and unnecessary surgeries.” MARKET SNAPSHOT Yesterday’s announcement comes nearly a year and a half after Risalto’s $1.5 million seed round , which was also headed by Health Catalyst Capital Management. That same year saw fundings for similar concierge services addressing different areas of care, such as SteadyMD ( $2.5 million in March 2018 ) and Accolade ( $50 million in April 2018 ). Further, it was only two months ago that Firefly announced its $10.2 million Series A round , and the appointment of athenahealth’s former firebrand Jonathan Bush as its executive chairman. ON THE RECORD "Health Catalyst Capital has focused on MSK as a major pain point in the healthcare system. By investing a second time in Risalto Health as it transforms MSK care, Health Catalyst Capital is furthering its mission of improving healthcare system access and quality while lowering costs," Charles Boorady, founding managing director at Health Catalyst Capital Management, said in a statement. “We have been very impressed by the progress made by Dan and the team at Risalto since our last investment. We are excited now to support their scale-up and roll-out to employers and health plans nationally. " Tags:
Health Catalyst Capital Management Investments
22 Investments
Health Catalyst Capital Management has made 22 investments. Their latest investment was in Holmusk as part of their Series B on December 12, 2021.
Health Catalyst Capital Management Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
12/6/2021 | Series B | Holmusk | No | 1 | ||
11/2/2021 | Series B - II | PierianDx | $30M | No | 11 | |
10/22/2021 | Series B | Click Therapeutics | $52M | Yes | 15 | |
9/9/2021 | Unattributed VC - II | |||||
6/21/2021 | Series C |
Date | 12/6/2021 | 11/2/2021 | 10/22/2021 | 9/9/2021 | 6/21/2021 |
---|---|---|---|---|---|
Round | Series B | Series B - II | Series B | Unattributed VC - II | Series C |
Company | Holmusk | PierianDx | Click Therapeutics | ||
Amount | $30M | $52M | |||
New? | No | No | Yes | ||
Co-Investors | |||||
Sources | 1 | 11 | 15 |
Health Catalyst Capital Management Portfolio Exits
2 Portfolio Exits
Health Catalyst Capital Management has 2 portfolio exits. Their latest portfolio exit was Clareto on April 12, 2022.
Health Catalyst Capital Management Fund History
2 Fund Histories
Health Catalyst Capital Management has 2 funds, including Health Catalyst Capital II.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
6/1/2020 | Health Catalyst Capital II | Multi-Stage Venture Capital | Open | $50.75M | 3 |
12/28/2016 | Health Catalyst Capital |
Closing Date | 6/1/2020 | 12/28/2016 |
---|---|---|
Fund | Health Catalyst Capital II | Health Catalyst Capital |
Fund Type | Multi-Stage Venture Capital | |
Status | Open | |
Amount | $50.75M | |
Sources | 3 |
Health Catalyst Capital Management Team
1 Team Member
Health Catalyst Capital Management has 1 team member, including current Managing Partner, Charles Boorady.
Name | Work History | Title | Status |
---|---|---|---|
Charles Boorady | Managing Partner | Current |
Name | Charles Boorady |
---|---|
Work History | |
Title | Managing Partner |
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.